title: The concept of 'borderline resectable' pancreatic cancer: limited foundations and limited future?
abstract: Pancreatic ductal adenocarcinoma (PDAC) is traditionally treated by a surgery-first approach. The development and adoption of the concept of borderline resectable PDAC, which extends the role of surgery, is based on the proposition that neoadjuvant therapy (NAT) will increase the resection rate, margin negative rate and overall survival. There are a number of issues with this concept and a critical review of these suggests that it is based on limited foundations and likely has a limited future.
authors.affiliation: HBP/Upper GI Unit, Department of General Surgery, Auckland City Hospital, Auckland, New Zealand;; Department of Surgery, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
authors.forename: John A
authors.initials: JA
authors.lastname: Windsor
authors.affiliation: Hepatobiliary and Oesophagogastric Unit, Division of Surgery and Perioperative Medicine, Flinders Medical Centre, Bedford Park, Adelaide, South Australia, Australia.
authors.forename: Savio George
authors.initials: SG
authors.lastname: Barreto
keywords: Morbidity; mortality; outcomes; research; survival